SciDev Limited posted a $2.14 million loss for the half-year ending December 2025, impacted by restructuring costs and a failed acquisition. Despite a 4% revenue dip, the company secured a major $19.5 million contract and maintains a strong balance sheet.
SciDev Limited reported a robust Q3 FY25 with revenue rising 10% and EBITDA tripling, driven by strategic US market expansion and a landmark PFAS remediation contract despite ongoing market challenges.